BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

587 related articles for article (PubMed ID: 30303856)

  • 1. Advances in the treatment of gastric cancer.
    Ilson DH
    Curr Opin Gastroenterol; 2018 Nov; 34(6):465-468. PubMed ID: 30303856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial.
    Tsuburaya A; Yoshida K; Kobayashi M; Yoshino S; Takahashi M; Takiguchi N; Tanabe K; Takahashi N; Imamura H; Tatsumoto N; Hara A; Nishikawa K; Fukushima R; Nozaki I; Kojima H; Miyashita Y; Oba K; Buyse M; Morita S; Sakamoto J
    Lancet Oncol; 2014 Jul; 15(8):886-93. PubMed ID: 24954805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in the treatment of gastric cancer.
    Ilson DH
    Curr Opin Gastroenterol; 2017 Nov; 33(6):473-476. PubMed ID: 28877045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized Phase II trial of systemic chemotherapy with and without trastuzumab followed by surgery in HER2-positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301 (Trigger Study).
    Kataoka K; Tokunaga M; Mizusawa J; Machida N; Katayama H; Shitara K; Tomita T; Nakamura K; Boku N; Sano T; Terashima M; Sasako M;
    Jpn J Clin Oncol; 2015 Nov; 45(11):1082-6. PubMed ID: 26355164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in the treatment of gastric cancer: 2020-2021.
    Ilson DH
    Curr Opin Gastroenterol; 2021 Nov; 37(6):615-618. PubMed ID: 34456227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chemotherapy for gastric cancer].
    Baba H; Kakeji Y; Oki E; Tokunaga E; Ushiro S; Watanabe M; Maehara Y
    Gan To Kagaku Ryoho; 2003 Nov; 30(12):1881-8. PubMed ID: 14650954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of subsequent docetaxel +/- ramucirumab and S-1 after nivolumab for patients with advanced non-small cell lung cancer.
    Tamura N; Horinouchi H; Sekine K; Matsumoto Y; Murakami S; Goto Y; Kanda S; Fujiwara Y; Yamamoto N; Ohe Y
    Thorac Cancer; 2019 May; 10(5):1141-1148. PubMed ID: 30913364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in the therapeutic landscape of oesophago-gastric cancers.
    Fokter Dovnik N; Smyth EC
    Curr Opin Oncol; 2021 Jul; 33(4):362-367. PubMed ID: 33720069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A case of gastric cancer showing response to first-line XP regimen after lymph node recurrence during the administration of S-1 as postoperative adjuvant chemotherapy].
    Mihara K; Yamashiro N; Nishiya S; Kemmochi T; Ito Y; Egawa T; Nagashima A
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):2358-60. PubMed ID: 25731522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial.
    Yoshida K; Kodera Y; Kochi M; Ichikawa W; Kakeji Y; Sano T; Nagao N; Takahashi M; Takagane A; Watanabe T; Kaji M; Okitsu H; Nomura T; Matsui T; Yoshikawa T; Matsuyama J; Yamada M; Ito S; Takeuchi M; Fujii M
    J Clin Oncol; 2019 May; 37(15):1296-1304. PubMed ID: 30925125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial.
    Di Bartolomeo M; Morano F; Raimondi A; Miceli R; Corallo S; Tamborini E; Perrone F; Antista M; Niger M; Pellegrinelli A; Randon G; Pagani F; Martinetti A; Fucà G; Pietrantonio F;
    Oncologist; 2020 Mar; 25(3):e460-e468. PubMed ID: 32162808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival Benefit of Neoadjuvant Chemotherapy with S-1 Plus Docetaxel for Locally Advanced Gastric Cancer: A Propensity Score-Matched Analysis.
    Kano M; Hayano K; Hayashi H; Hanari N; Gunji H; Toyozumi T; Murakami K; Uesato M; Ota S; Matsubara H
    Ann Surg Oncol; 2019 Jun; 26(6):1805-1813. PubMed ID: 30977014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Gastric Cancer Surgical Study Group.
    Nakajima T; Nashimoto A; Kitamura M; Kito T; Iwanaga T; Okabayashi K; Goto M
    Lancet; 1999 Jul; 354(9175):273-7. PubMed ID: 10440302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perioperative chemotherapy for locally advanced gastric cancer in Japan: current and future perspectives.
    Tokunaga M; Sato Y; Nakagawa M; Aburatani T; Matsuyama T; Nakajima Y; Kinugasa Y
    Surg Today; 2020 Jan; 50(1):30-37. PubMed ID: 31612329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy.
    Shitara K; Chin K; Yoshikawa T; Katai H; Terashima M; Ito S; Hirao M; Yoshida K; Oki E; Sasako M; Emi Y; Tsujinaka T
    Gastric Cancer; 2017 Jan; 20(1):175-181. PubMed ID: 26626800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy in esophagogastric cancer.
    Ilson DH
    Clin Adv Hematol Oncol; 2021 Oct; 19(10):639-647. PubMed ID: 34637430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regimens (JCOG0407).
    Nishina T; Boku N; Gotoh M; Shimada Y; Hamamoto Y; Yasui H; Yamaguchi K; Kawai H; Nakayama N; Amagai K; Mizusawa J; Nakamura K; Shirao K; Ohtsu A;
    Gastric Cancer; 2016 Jul; 19(3):902-10. PubMed ID: 26386560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized phase III trial of postoperative adjuvant therapy with S-1 alone versus S-1 plus PSK for stage II/IIIA gastric cancer: Hokuriku-Kinki Immunochemo-Therapy Study Group-Gastric Cancer (HKIT-GC).
    Ueda Y; Fujimura T; Kinami S; Hirono Y; Yamaguchi A; Naitoh H; Tani T; Kaji M; Yamagishi H; Miwa K;
    Jpn J Clin Oncol; 2006 Aug; 36(8):519-22. PubMed ID: 16803844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in the treatment of gastric cancer: 2019.
    Ilson DH
    Curr Opin Gastroenterol; 2019 Nov; 35(6):551-554. PubMed ID: 31436556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Long-Term Disease-Free Survival through Postoperative Chemotherapy in a Case of Gastric Cancer with Peritoneal Dissemination].
    Nakade H; Matsumoto S; Wakatsuki K; Tanaka T; Migita K; Ito M; Kunishige T; Kitano M; Nakatani M; Nakajima Y
    Gan To Kagaku Ryoho; 2015 Nov; 42(12):2055-7. PubMed ID: 26805262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.